Search Results

You are looking at 1 - 10 of 27 items for :

  • "suboptimal response" x
Clear All
Full access

Giuseppe Saglio and Carmen Fava

define failure and suboptimal response at each time point, and the consensus and differences between the groups. Table 1 European LeukemiaNet and NCCN Parameters to Define Failure and Suboptimal Response Optimal response to imatinib

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

benefit those with hematologic resistance or those who never had a cytogenetic response with standard-dose imatinib. Dose escalation of imatinib might be beneficial for patients with suboptimal response to imatinib, 400 mg daily (see Suboptimal Response

Full access

Javier Pinilla-Ibarz and Alfonso Quintás-Cardama

Biol Chem 2000 ; 275 : 18581 – 18585 . 27 Alvarado Y Kantarjian H O’Brien S . Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia

Full access

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen and Diana I. Brixner

modifications were defined as a dose increase or decrease compared with the starting dose. Reasons for dose modifications were characterized in relation to an ADE, suboptimal response, or treatment failure. Imatinib discontinuation was defined as a change to an

Full access

Jorge Cortes, John M. Goldman and Timothy Hughes

recommendations, however ( Table 2 ). 2 - 4 The ELN defines failure and suboptimal response and includes an additional response category (warnings), whereas the NCCN Guidelines do not formally define suboptimal response, but rather define target responses at

Full access

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus

organic cation transporter-1 (hOCT1) have been reported as being the most powerful predictor of response to imatinib. 91 White et al. 92 recently reported that most patients with suboptimal response to imatinib have low hOCT1 activity. In the updated

Full access

Jerald P. Radich

2009 ; 27 : 6041 – 6051 . 8. Marin D Milojkovic D Olavarria E . European LeukemiaNet criteria for failure of suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Full access

Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos and Jason Y. Park

survival rates of 80% to 100% with complete resection. However, tumors located along the midline and disseminated PAs have a suboptimal response to conventional chemotherapy and a relatively poor prognosis. 7 There are several reports of successful

Full access

Jerald P. Radich

first blush,” he acknowledged. Although many patients who respond to imatinib are likely to experience long-term benefits, about one-third of patients do not. 2 Reasons for a suboptimal response include an inability to tolerate imatinib therapy, no

Full access

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler

for drug resistance . Blood 2004 ; 104 : 3739 – 3745 . 70 White DL Saunders VA Dang P . Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of